Larischa de Wet

Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells

E. Platz, A. D. De Marzo, J. L. Coloff, 2022, Oncogene.

SOX2 Mediates Metabolic Reprogramming of Prostate Cancer Cells

A. D. De Marzo, J. L. Coloff, P. Mu, 2021, Oncogene.

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Krishna R. Kalari, Kevin J. Thompson, K. Kalari, 2018, Clinical Cancer Research.

Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.

J. Collier, Yaoying Wu, Ye F. Tian, 2018, Macromolecular bioscience.

Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth

S. Conzen, Jacob Kach, W. Chan, 2017, Molecular Cancer Therapeutics.

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.

A. Dey, D. V. Vander Griend, Steven Kregel, 2023, Cancer letters.